Recurrence of Primary Biliary Cirrhosis After Liver Transplantation: Histologic Estimate of Incidence and Natural History
Overview
General Surgery
Affiliations
The goals of this study were to determine the rate of recurrent primary biliary cirrhosis (PBC) after orthotopic liver transplantation (OLT) based on strict morphologic criteria and to evaluate histologic progression of recurrent PBC over time. Strict criteria for PBC recurrence were established as the presence of a florid duct lesion or destructive lymphocytic cholangitis within a dense portal infiltrate. Of the 784 OLTs performed at the Mayo Clinic during the first 12 years of the program, 100 met criteria for the PBC study group, and 35 met criteria for the control group. Strict histologic criteria for recurrent PBC were observed in 17 of 100 (17%) study patients (14 with florid duct lesion, 3 with destructive lymphocytic cholangitis within dense portal infiltrate). Mean follow-up for the PBC group was 4.7 years (range, 1.0 to 13.8). Mean time to recurrence was 3.7 years (median, 3.1; range, 0.3 to 7.9). In those who met strict criteria for recurrent PBC, 2 of 17 progressed to septal fibrosis (stage 3). No florid duct lesions, destructive lymphocytic cholangitis, or septal fibrosis were observed in the control group. Other less specific morphologic features of PBC (portal infiltrates, plasma cells, dense lymphoplasmacytic infiltrates, and lymphocytic cholangitis) were also evaluated in the course of this study. Based on strict criteria, a conservative histologic estimate of the rate of recurrent PBC is 17% with a mean of 4.7 years of follow-up. When criteria for histologic recurrence are expanded to include moderate lymphocytic cholangitis with lymphoplasmacytic portal infiltrate, the recurrence rate of PBC is estimated as 26%.
Mechanisms governing bystander activation of T cells.
Yosri M, Dokhan M, Aboagye E, Moussawy M, Abdelsamed H Front Immunol. 2024; 15:1465889.
PMID: 39669576 PMC: 11635090. DOI: 10.3389/fimmu.2024.1465889.
van Hooff M, de Veer R, Karam V, Adam R, Taimr P, Polak W JHEP Rep. 2024; 6(8):101100.
PMID: 39045337 PMC: 11263784. DOI: 10.1016/j.jhepr.2024.101100.
Mehtani R, Rathi S J Clin Exp Hepatol. 2024; 14(6):101432.
PMID: 38975605 PMC: 11222954. DOI: 10.1016/j.jceh.2024.101432.
Lee D, Ponder R, Lee K, Menegas S, Fan G, Chou H Hepatol Int. 2022; 17(3):720-734.
PMID: 36575337 PMC: 10225314. DOI: 10.1007/s12072-022-10468-8.
Pretransplant Evaluation and Liver Transplantation Outcome in PBC Patients.
Mijic M, Saric I, Delija B, Lalovac M, Sobocan N, Radetic E Can J Gastroenterol Hepatol. 2022; 2022:7831165.
PMID: 35910038 PMC: 9337972. DOI: 10.1155/2022/7831165.